Eton Pharmaceutcials
ETON
35 hedge funds and large institutions have $22.5M invested in Eton Pharmaceutcials in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
48% more capital invested
Capital invested by funds: $15.1M → $22.5M (+$7.33M)
13% more funds holding
Funds holding: 31 → 35 (+4)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
0.54% less ownership
Funds ownership: 23.47% → 22.93% (-0.54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Acuitas Investments
Seattle,
Washington
|
+$1.71M |
| 2 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$337K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$201K |
| 4 |
Lido Advisors
Los Angeles,
California
|
+$160K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$54.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$1.26M |
| 2 |
AIC
AWM Investment Company
New York
|
-$1.11M |
| 3 |
WIM
Westside Investment Management
Santa Monica,
California
|
-$135K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$36.2K |
| 5 |
Morgan Stanley
New York
|
-$19.8K |
ETON Hedge Fund Activity: Q1 2023 in Review
35 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Eton Pharmaceutcials (ETON) for Q1 2023, worth a combined $22.5M — up 48% from $15.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ETON positions and 5 closed out — a net gain of 5 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Acuitas Investments, opening a new position worth an estimated $1.71M. The largest seller was Roumell Asset Management, exiting entirely with an estimated $1.26M sold.
- 35 institutional investors held Eton Pharmaceutcials (ETON) as of Q1 2023, up from 31 in Q4 2022.
- Funds reported $22.5M of Eton Pharmaceutcials stock for Q1 2023, up 48% quarter-over-quarter.
- 10 funds opened new Eton Pharmaceutcials positions in Q1 2023 and 5 closed out, a net change of +5 holders.
- The largest Eton Pharmaceutcials buyer in Q1 2023 was Acuitas Investments, an estimated $1.71M added.
- The largest Eton Pharmaceutcials seller in Q1 2023 was Roumell Asset Management, an estimated $1.26M sold.
Based on aggregated 13F filings for Q1 2023.